Evidence map›Paper›PMID 40234692›Full record

ArticleCommunications biology2025

A nanobody that binds to the backside of the ubiquitin conjugating enzyme Ube2G2 differentially affects interactions with its partner E3 Ligases.

Pavana Suresh, Charlotte Wijne, Zhen-Yu J Sun, Nanette Becht, Ishani Sahay, Novalia Pishesha, Hidde Ploegh

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pavana SureshProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. pavana.suresh@childrens.harvard.edu.ORCID http://orcid.org/0000-0003-1597-6818
Charlotte WijneProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Zhen-Yu J SunDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nanette BechtProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Ishani SahayProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Novalia PisheshaDivision of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Hidde PloeghProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1090-6071

Funding

Imposing order on the family of ubiquitin-conjugating (E2) enzymes through intracellular perturbation with nanobodiesDP1AI150593 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI PLOEGH, HIDDE L. · 2019 to 2023
$7.1M
Drosophila models of human mitochondrial diseasesR24OD035556 · OD · HARVARD MEDICAL SCHOOL · PI NORBERT PERRIMON · 2023 to 2026
$3.3M
UCSD PRIDE Faculty Development Program in Cardiovascular SciencesR25HL145817 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Robert Scott Ross, Joann Trejo · 2019 to 2026
$3.3M
NHLBI NIH HHS R25 HL145817NIAID NIH HHS DP1 AI150593NIH HHS R24 OD035556U.S. Department of Health & Human Services | National Institutes of Health (NIH) 5DP1AI150593-05
6 · The paper itself

Abstract

Ubiquitin conjugating E2 enzymes are a set of ~40 proteins that play a central role in the ubiquitination cascade. They transfer ubiquitin from an E1 enzyme to substrates with the help of an E3 enzyme. The members of the E2 family share structural similarity in their conserved UBC fold. This complicates an assessment of the specificity of E2-E3 interactions. We identified a nanobody that binds to the 'backside' region of Ube2G2, an E2 involved in ER protein quality control. This binding does not affect ubiquitin loading but shows varying degrees of inhibition on E3-mediated ubiquitination, in the order HRD1 > CHIP >> TRC8. A naturally occurring segment that binds Ube2G2's backside, referred to as G2BR (Ube2G2 Binding Region), shows a similar inhibitory effect depending on the identity of the interacting E3. The G2BR in the Ube2G2-cognate E3 Gp78 enhances Ube2G2's activity, but its deletion results in a similar inhibition upon addition of the nanobody. Occupation of a single binding site on an E2 can thus affect its interactions with different E3s.

Indexed as

Single-Domain AntibodiesUbiquitin-Conjugating EnzymesUbiquitin-Protein LigasesBinding SitesHumansProtein BindingUbiquitinationSingle-Domain AntibodiesUBE2G2 protein, humanUbiquitin-Conjugating EnzymesUbiquitin-Protein Ligases

Identifiers

PMID40234692
PMCPMC12000298

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.